Compare BHF & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | LGND |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2018 | 1997 |
| Metric | BHF | LGND |
|---|---|---|
| Price | $50.37 | $284.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $57.71 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 945.0K | 157.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.06 | ★ 2886.36 |
| EPS | ★ 2.84 | 1.63 |
| Revenue | ★ $6,766,000,000.00 | $141,102,000.00 |
| Revenue This Year | $27.10 | $1.25 |
| Revenue Next Year | $1.09 | $19.41 |
| P/E Ratio | ★ $18.01 | $176.72 |
| Revenue Growth | ★ 43.23 | 29.48 |
| 52 Week Low | $44.65 | $161.82 |
| 52 Week High | $66.80 | $326.63 |
| Indicator | BHF | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 26.76 | 50.98 |
| Support Level | N/A | $286.99 |
| Resistance Level | $63.74 | $317.49 |
| Average True Range (ATR) | 1.44 | 8.03 |
| MACD | 0.09 | 0.64 |
| Stochastic Oscillator | 22.77 | 83.11 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.